GE Healthcare expands MRI contrast media product range in Europe with launch of macrocyclic agent ClariscanTM
March 01 2017 - 2:00AM
Business Wire
Clariscan builds on GE Healthcare’s wide range
of imaging products, services and support delivered to radiology
professionals worldwide
Growing its range of magnetic resonance imaging (MRI) contrast
media options available to patients and radiologists, GE Healthcare
today announced the launch of Clariscan™ (gadoteric acid) at the
European Congress of Radiology (ECR) 2017 meeting. Clariscan is a
gadolinium-based contrast agent (GBCA) designed to support
effective visualisation of abnormalities in the brain, spine and
associated tissues, and will be provided alongside GE Healthcare’s
comprehensive support services and solutions to healthcare
practitioners worldwide.
Emmanuel Ligner, General Manager of Core Imaging for GE
Healthcare Life Sciences, said: “Gadolinium-based agents are known
to be a gold-standard detection tool in MR imaging, offering
improved contrast between normal and pathological tissue to enable
rapid detection of abnormalities. It is important that radiologists
are able to make a contrast media selection dependent on the needs
of individual patients.”
“We are therefore pleased to add Clariscan to the family of GE
contrast media and imaging products alongside our existing linear
agent for MRI, Omniscan, which has been used in routine diagnostic
practice for over 25 years with over 80 million administrations. We
believe macrocyclic Clariscan, manufactured using a proprietary GE
process, extends choice for radiology professionals, backed by the
well-established quality, reliability and surrounding services GE
customers have come to expect.”
As a macrocyclic and ionic GBCA, Clariscan is available at a
range of doses in vials and pre-filled syringes. It is the latest
in a line of products and services provided by GE Healthcare to the
radiology community, which include a wide range of contrast media
as well as a portfolio of systems and products across MRI, X-ray/CT
and ultrasound modalities. GE Healthcare has provided comprehensive
partnership and support services to the radiology profession for
over 30 years.
Demand for contrast media has significantly increased over the
past decade due to rapid procedural advancements in MR imaging,
elevating the importance of uninterrupted and sustainable product
supply, as well as meeting the individual needs of patients
undergoing diagnostic procedures. The company invested over USD 65
million in its worldwide supply network between 2013 and 2016, to
increase manufacturing capacity. GE contrast media products are
used in more than 70 million procedures per year, equivalent to
injection in two patients per second. The company provides
best-in-class service and supply of its contrast media portfolio to
radiologists across all medical, technical and logistical aspects
of imaging.
Clariscan™ has been approved using the decentralised procedure
with marketing authorisation in place in Norway. It will be
introduced to European countries across 2017. Healthcare
professionals are advised to speak to their local GE Healthcare
representative for information on local availability.
About GE Healthcare
GE Healthcare provides transformational medical technologies and
services to meet the demand for increased access, enhanced quality
and more affordable healthcare around the world. GE (NYSE: GE)
works on things that matter - great people and technologies taking
on tough challenges. From medical imaging, software & IT,
patient monitoring and diagnostics to drug discovery,
biopharmaceutical manufacturing technologies and performance
improvement solutions, GE Healthcare helps medical professionals
deliver great healthcare to their patients. For more information
about GE Healthcare, visit our website at www.gehealthcare.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170228005161/en/
GE HealthcareErin BryantErin.Bryant@ge.com+1 203 450
5326@GEHealthcare
GE Aerospace (NYSE:GE)
Historical Stock Chart
From Mar 2024 to Apr 2024
GE Aerospace (NYSE:GE)
Historical Stock Chart
From Apr 2023 to Apr 2024